Elevance Health Analyst Ratings
Morgan Stanley Initiates Coverage On Elevance Health With Overweight Rating, Announces Price Target of $643
Elevance Health Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Elevance Health, Maintains $600 Price Target
Stephens & Co. Reiterates Overweight on Elevance Health, Maintains $615 Price Target
Elevance Health Analyst Ratings
Elevance Health Analyst Ratings
B of A Securities Maintains Buy on Elevance Health, Raises Price Target to $646
Elevance Health Analyst Ratings
JP Morgan Maintains Overweight on Elevance Health, Raises Price Target to $631
Wells Fargo Keeps Their Buy Rating on Elevance Health (ELV)
Elevance Health Analyst Ratings
Baird Initiates Elevance Health With Outperform Rating, $649 Price Target
Elevance Health Inc: J.P. Morgan raises price target from $628 to $631
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV), Agilon Health (AGL) and Boston Scientific (BSX)
Argus Raises Elevance Health's Price Target to $600 From $540
Elevance Health Analyst Ratings
Elevance Health Outperforms With Strong MLR and EPS Growth Potential: A Buy Rating Justified
Elevance Health: Strong Q1 Performance and Strategic Initiatives Underpin Buy Rating
Barclays: Maintaining the Elevance Health (ELV.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $584.00 to $621.00.